PledPharma publishes a supplement to the prospectus
November 12, 2020
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS), ANY STATE OF THE UNITED STATES INCLUDING THE DISTRICT OF COLUMBIA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.
The Board of Directors of PledPharma AB (publ) (“PledPharma” or “the Company”) has prepared a supplement to the prospectus regarding invitation to acquire shares in the in PledPharma and the admission to trading of new issued shares on Nasdaq Stockholm which was approved by the Swedish Financial Supervisory Authority ("SFSA") (Sw. Finansinspektionen) on 5 November, 2020 and published by the Company on the same date. The supplementary prospectus, which has been prepared due to the publishing of the Company's interim-report for the period 1 January – 30 September 2020 yesterday, has today been approved by the SFSA and published on the Company's website.
The supplement has been prepared by reason of PledPharma, during the subscription period in the ongoing preferential rights issue of shares (the "Rights Issue"), on 11 November 2020 published the Company’s interim report for the period 1 January-30 September 2020.
The supplement has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "Prospectus Regulation") and has today, 12 November 2020, been approved by the SFSA and published on the Company's website. The supplementary prospectus forms a part of the prospectus and shall in all respects be read together with the prospectus. The prospectus and the supplementary prospectus are available on the Company's website (www.pledpharma.se), Pareto Securities’ website (www.paretosec.com) and ABG Sundal Colliers’ website (www.abgsc.com).
Investors who before the publication of the supplement have applied for, or in any other manner consented to, subscription of shares in the Rights Issue have, in accordance with Article 23 of the Prospectus Regulation, the right to withdraw their application or consent within two working days from the publication of the supplementary prospectus, i.e. up to and including 16 November 2020. A withdrawal shall be made in writing to Aktieinvest FK, Emittentservice/PledPharma, Box 7415, 103 91 Stockholm. Applications that are not withdrawn within the prescribed time will remain binding and no measure is required for investors wishing to withhold their subscription of shares.
For complete terms and other information about the Rights Issue, please refer to the prospectus and the supplement.
Financial and legal advisors
ABG Sundal Collier and Pareto Securities act as Joint Bookrunners for the Rights Issue. Advokatfirman Lindahl is the legal advisor to PledPharma and Baker McKenzie is the legal advisor to the Joint Bookrunners.